Research programme: rheumatoid arthritis gene therapies - Arthrogen

Drug Profile

Research programme: rheumatoid arthritis gene therapies - Arthrogen

Alternative Names: ART-D01; ART-G01; ART-T01; ART-T02; rAAV5.interferon-β.stuffer

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arthrogen
  • Class Gene therapies
  • Mechanism of Action Chemokine inhibitors; Gene transference; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Netherlands (Intra-articular)
  • 17 Jan 2011 Preclinical development is ongoing Netherlands
  • 13 Jun 2009 Pharmacokinetics data from a preclinical trial in rheumatoid arthritis presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top